Verrica Pharmaceuticals Inc. Cash Flow Statement
VRCA|5 years of annual SEC 10-K data (FY2021-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 5 fiscal years. All figures from audited SEC 10-K filings.
Verrica Pharmaceuticals Inc. used $61M in operating cash flow and negative free cash flow of $61M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -3.86 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Net Income | -$76.6M | -$67.0M | -$24.5M | -$35.1M | -$42.7M |
| Depreciation & Amortization | $342.0K | $530.0K | $454.0K | $244.0K | $43.0K |
| Operating Cash Flow | -$60.9M | -$38.6M | -$18.6M | -$27.6M | -$30.2M |
| Capital Expenditures | $27.0K | $362.0K | $302.0K | $883.0K | $1.5M |
| Free Cash Flow | -$61.0M | -$38.9M | -$19.0M | -$28.5M | -$31.7M |
| FCF Margin | -805.6% | -759.9% | -209.8% | -237.2% | -264.0% |